Europe Contrast Media Market

The Europe contrast media market is projected to reach USD 3.19 billion by 2031 from USD 2.22 billion in 2026, at a CAGR of 7.5%. The market is driven by the increasing demand for advanced diagnostic imaging, fueled by a rise in chronic diseases such as cardiovascular diseases, cancer, and neurological disorders. As the aging population grows, there is a rising need for both CT and MRI scans. This shift in healthcare focuses on prevention, creating a demand for more advanced iodinated contrast media and gadolinium-based contrast media that can deliver clearer images for accurate diagnoses. Additionally, technologies such as low osmolarity and artificial intelligence-enhanced diagnostic imaging improve patient safety and increase diagnostic precision, leading to the rapid adoption of these innovations in hospitals.

Stringent regulations in the EU, specifically the EU MDR, along with an effective reimbursement structure, are also contributing to market growth. Additionally, public health campaigns are leading to an increased number of people being screened. Infrastructure improvements in Central and Western Europe, combined with the growing acceptance of telemedicine solutions, are facilitating more radiology and interventional procedures. Furthermore, major global companies like Bayer and GE Healthcare are heavily investing in research & development, which enhances supply chain capabilities and provides customized solutions. As a result, the market is projected to achieve a positive CAGR through 2030.

To know about the assumptions considered for the study download the pdf brochure

The major companies in the Europe contrast media market include Bayer AG (Germany), Bracco Imaging S.P.A. (Italy), GE Healthcare (US), Guerbet (France), and Lantheus Medical Imaging (US). The competitive landscape focuses on analyzing the key growth strategies these leading players are adopting from 2023 to 2025 in order to expand their global presence and increase their market share.

The primary growth strategies employed by major companies in this market include product approvals & launches, acquisitions, collaborations, partnerships, and agreements. In the past three years, product approvals & launches have emerged as the most widely adopted organic growth strategies among market players aiming to expand their market share.

Bayer AG (Germany) is a global life sciences company headquartered in Leverkusen, Germany. Its business is organized into three main divisions: Pharmaceuticals, Consumer Care, and Crop Science. The Radiology division of Bayer is a leading player in the Europe contrast media market, backed by a strong brand and a broad network of hospitals. Bayer offers a wide range of products, including Ultravist for CT/X-ray scans and Gadovist for magnetic resonance imaging. Innovation is a key strategy for Bayer, exemplified by products like Gadoquatrane, a new-generation injectable contrast agent that has recently been submitted for EU approval. This product emerged from the QUANTI CNS phase III studies, which demonstrated a potential dose reduction of up to 60% while also improving safety and environmental sustainability. Additionally, Bayer has utilized artificial intelligence through its proprietary solution, Calantic, to enhance procedure efficiency. This advancement is part of Ultravist's expansion into pediatric applications and was highlighted at ECR 2015. The production networks established by Bayer comply with Medical Device Regulation (MDR) requirements, supporting the development and increasing the market share of Gadovist in Magnetic Resonance Angiography (MRA) and breast MRI in European markets.

Bracco Imaging S.P.A (Italy) is an Italian company founded in 1927 and headquartered in Milan. It is a leading player in the field of diagnostic imaging worldwide. With over 3,300 employees, Bracco generates significant revenue from contrast agents, injectors, and solutions used in X-ray/CT, MRI, ultrasound, and nuclear medicine. The company ranks second in the Europe contrast media market, following Bayer, and offers a comprehensive portfolio of products for X-ray/CT, which it markets through direct sales, joint ventures, and partnerships in more than 100 countries. Key strategic goals for Bracco include obtaining regulatory approvals for new indications and driving product innovation, particularly in the development of high-relaxivity agents. The company is also committed to sustainability, as demonstrated by its collaboration with Zereau at ECR 2025, focusing on iodine and gadolinium wastewater filtration systems designed to reduce environmental impact. Joint ventures, such as the one established in December 2021 with Guerbet for the manufacturing and R&D of Gadopiclenol, along with the implementation of AI-enabled administrative systems, enhance Bracco's competitive position. The company prioritizes patient safety, dose optimization, and eco-friendly practices in radiology, adhering to EU MDR standards.

GE HealthCare (US), headquartered in Chicago, Illinois, is a leading global medical technologies firm. It operates through four primary business segments: Medical Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, which focuses on the development and sales of contrast media and radiopharmaceuticals. GE HealthCare has operations in over 160 countries worldwide. Its main manufacturing plants in Europe are located in Ireland, Norway, and Poland. The company generates 26% of its sales from the EMEA (Europe, Middle East, and Africa) region and provides combined imaging contrast solutions to hospitals. In the Europe contrast media market, where GE HealthCare ranks third in cumulative sales, the company is expanding its production capacity. It plans to invest USD 138 million in a contrast production facility in Cork, Ireland, by 2025, to meet the increasing demand for interventions. Additionally, it will invest USD 80 million to enhance production capacity for iodinated contrast in Lindesnes, Norway, before 2025. GE HealthCare focuses on three key strategies: improving supply chain resilience, addressing regulatory issues (MDR), and innovatively integrating contrast media with existing CT and MRI systems. These efforts aim to improve the diagnosis of chronic diseases while allowing the company to stand out among competitors in an already mature market.

Market Ranking

In the Europe contrast media market, leading companies hold a significant market share due to their strong brand reputation, robust research & development pipelines, and long-term agreements with hospitals and diagnostic centers. Bayer AG and GE HealthCare are the two main players, offering a comprehensive range of iodinated and gadolinium-based products, strong connections to new imaging technologies, and extensive manufacturing and distribution networks throughout the region. Following them are Bracco Imaging and Guerbet, which leverage their specialized expertise, innovative product formulations, and close relationships with the European medical community. Lantheus Medical Imaging also holds a favorable position in the market due to its niche diagnostic products and strategic geographical expansion, which intensifies competition amidst high entry barriers and innovation-driven growth.

Related Reports:

Europe Contrast Media Market by Product (Microbubble, Iodine, Gadolinium, Barium-based), Modality (CT, MRI, Ultrasound), Indication (Cancer, GIT, CVD, Musculoskeletal, Neurology, Urology), Route of Administration (IV, Oral), End User - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]